Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 12;101(4):adv00429.
doi: 10.2340/00015555-3791.

Localized Injection-site Toxic Erythema of Chemotherapy: An Under-recognized Acquaintance Revisited

Elisa Ríos-Viñuela  1 , Eduardo Bernia, Tomás Toledo-Pastrana, Celia Requena, Adrián Diago, Carlos Serra-Guillén, Beatriz Llombart, Victor Traves, Eduardo Nagore, Carlos Guillén, Onofre Sanmartin
Affiliations

Localized Injection-site Toxic Erythema of Chemotherapy: An Under-recognized Acquaintance Revisited

Elisa Ríos-Viñuela et al. Acta Derm Venereol. .
No abstract available

Keywords: chemotherapy adverse effect; chemotherapy skin eruption; cytostatic drugs; drug reaction; localized epidermal necrolysis; toxic erythema of chemotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Clinical features and histological features. (a) Erythema multiforme (EM)-like presentation: erythematous macules and papules with vesicular changes, following a linear path along the affected vein. (b) Fixed drug eruption(FDE)-likepresentation: localized erythematous,inflammatory plaques at the infusion site, also showing vesicular changes. (c) Persistent serpentine supravenous hyperpigmentation/eruption presentation: non-inflammatory, linear hyperpigmentation following the infusion vein. (d) Mild interface dermatitis with basal vacuolar degeneration, and scattered necrotic keratinocytes (haematoxylin-eosin, 200× original magnification). (e) Mitotic retention figures scattered in supra-basal layers (haematoxylineosin, 400× original magnification).
See this image and copyright information in PMC

References

    1. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59: 524–529. - PubMed
    1. Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol 2014; 71: 217.e1-217.e11. - PubMed
    1. Sanmartin O, Beato C, Suh-Oh HJ, Aragon I, Espana A, Majem M, et al. . Clinical management of cutaneous adverse events in patients on chemotherapy: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Actas Dermosifiliogr 2019; 110: 448–459. - PubMed
    1. Sibaud V, Fricain JC, Baran R, Robert C. Pigmentary disorders induced by anticancer agents. Part I: Chemotherapy. Ann Dermatol Venereol 2013; 140: 183–196. - PubMed
    1. Sibaud V. Toxic erythema of chemotherapy. Ann Dermatol Venereol 2015; 142: 81–84. - PubMed

LinkOut - more resources